Cardiology
Clinical
Suboptimal statin response predicts future risk
What are the differences in LDL cholesterol responses among primary prevention patients prescribed statins, and do those differences predict...
News
How to reboot elective CV procedures after COVID-19 lockdown
News
COVID-19: ‘dramatic’ surge in out-of-hospital cardiac arrests in NYC
At the height of the COVID-19 pandemic in New York City, first responders faced nearly triple the number of calls for cardiac arrest compared with...
News
Dapagliflozin benefits low-EF heart failure regardless of diuretic dose: DAPA-HF
The trial that turned an SGLT2 inhibitor into a heart failure drug also has clues to mechanisms behind the observed benefits. Contrary to early...
News
VA readmissions program not linked to increased death
Unlike CMS’s hospital readmissions program, the VA’s program had no financial penalties. A new analysis shows heart failure readmissions are down...
News
ED visits for life-threatening conditions declined early in COVID-19 pandemic
Visits for MI, stroke, and hypoglycemic crisis dropped 10%-23% over the first 10 weeks.
News
Cost of preventable adult hospital stays topped $33 billion in 2017
Heart failure, diabetes, and COPD were the most expensive preventable conditions.
News
CVD risk continues to fall down to systolic BP of 90 mm HG
“From an individual level we can now say that in healthy individuals, a systolic pressure in the 90s is not too low. It is a positive thing.”
Opinion
Preventing arrhythmias and QTc prolongation in COVID-19 patients on psychotropics
Psychotropics associated with QTc interval prolongation should be discontinued (or substituted with a low-risk agent) if a patient presents with...
News
DAPA-HF: Dapagliflozin slows T2D onset in heart failure patients